Attributes | Values |
---|
rdf:type
| |
Description
| - Savčí peroxidázy aktivují protinádorový lék elipticin, což umožňuje tvorbu deoxyguanozinových adduktů v DNA, které jsou shodné s addukty vyvolanými 12-hydroxyelipticinem a 13-hydroxyelipticinem in vivo (cs)
- Ellipticine is a potent antineoplastic agent, whose mode of action is considered to be based mainly on DNA intercalation, inhibition of topoisomerase II and cytochrome P450-mediated formation of covalent DNA adducts.
- Ellipticine is a potent antineoplastic agent, whose mode of action is considered to be based mainly on DNA intercalation, inhibition of topoisomerase II and cytochrome P450-mediated formation of covalent DNA adducts. (en)
|
Title
| - Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine
- Savčí peroxidázy aktivují protinádorový lék elipticin, což umožňuje tvorbu deoxyguanozinových adduktů v DNA, které jsou shodné s addukty vyvolanými 12-hydroxyelipticinem a 13-hydroxyelipticinem in vivo (cs)
- Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine (en)
|
skos:prefLabel
| - Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine
- Savčí peroxidázy aktivují protinádorový lék elipticin, což umožňuje tvorbu deoxyguanozinových adduktů v DNA, které jsou shodné s addukty vyvolanými 12-hydroxyelipticinem a 13-hydroxyelipticinem in vivo (cs)
- Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine (en)
|
skos:notation
| - RIV/00064203:_____/07:1577!RIV08-MSM-00064203
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(GA203/06/0329), Z(MSM0021620808), Z(MSM0021620813)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064203:_____/07:1577
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - ellipticine; anticancer drug; peroxidase; cytochrome P450; DNA adduct; xenobiotic-metabolizing enzymes; covalent binding; breast-cancer; catalyzed activation; elliptinium acetate; mediated oxidation; cytochromes p450; antitumor agent; cell-line; sudan-i (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - CH - Švýcarská konfederace
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - International Journal of Cancer
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |